TY - JOUR
T1 - Towards Preanalytical Best Practices for Liquid Biopsy Studies
T2 - A BLOODPAC Landscape Analysis
AU - Lockwood, Christina M.
AU - Merker, Jason D.
AU - Bain, Elizabeth
AU - Compton, Caroline
AU - Grossman, Robert L.
AU - Johann, Donald
AU - Jones, Frederick
AU - Jones, Gregory
AU - Kreifels, Matthew
AU - LeBlang, Suzanne
AU - Lee, Jerry S.H.
AU - Lyle, John
AU - Martini, Jean Francois
AU - Saunders, Lauren
AU - Scher, Howard
AU - Somiari, Stella
AU - Stewart, Mark
AU - Vinson, Jacob
AU - Leiman, Lauren C.
N1 - Publisher Copyright:
© 2024 The Author(s). Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
PY - 2024
Y1 - 2024
N2 - BLOODPAC is a public-private consortium that develops best practices, coordinates clinical and translational research, and manages the BLOODPAC Data Commons to broadly support the liquid biopsy community and accelerate regulatory review to aid patient accessibility. BLOODPAC previously recommended 11 preanalytical minimal technical data elements (MTDEs) for BLOODPAC-sponsored studies and data submitted to BLOODPAC Data Commons. The current landscape analysis evaluates the overlap of the BLOODPAC MTDEs with current best practices, guidelines, and standards documents related to clinical and research liquid biopsy applications. Our findings indicate an existing high degree of concordance among these documents. Where differences exist, the BLOODPAC preanalytical MTDEs can be considered a minimal practicable set for organizations to utilize. These MTDEs were developed following extensive examination of best practices and iterative conversations with the U.S. FDA. BLOODPAC recommends the use of these MTDEs in submissions to data commons and to support liquid biopsy clinical trials and research globally.
AB - BLOODPAC is a public-private consortium that develops best practices, coordinates clinical and translational research, and manages the BLOODPAC Data Commons to broadly support the liquid biopsy community and accelerate regulatory review to aid patient accessibility. BLOODPAC previously recommended 11 preanalytical minimal technical data elements (MTDEs) for BLOODPAC-sponsored studies and data submitted to BLOODPAC Data Commons. The current landscape analysis evaluates the overlap of the BLOODPAC MTDEs with current best practices, guidelines, and standards documents related to clinical and research liquid biopsy applications. Our findings indicate an existing high degree of concordance among these documents. Where differences exist, the BLOODPAC preanalytical MTDEs can be considered a minimal practicable set for organizations to utilize. These MTDEs were developed following extensive examination of best practices and iterative conversations with the U.S. FDA. BLOODPAC recommends the use of these MTDEs in submissions to data commons and to support liquid biopsy clinical trials and research globally.
UR - http://www.scopus.com/inward/record.url?scp=85201719476&partnerID=8YFLogxK
U2 - 10.1002/cpt.3416
DO - 10.1002/cpt.3416
M3 - Article
AN - SCOPUS:85201719476
SN - 0009-9236
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
ER -